Title 21 CFR Part 11 1
Title 21 CFR Part 11
Title 21 CFR Part 11 of the Code of Federal Regulations deals with the Food and Drug Administration (FDA)
guidelines on electronic records and electronic signatures in the United States. Part 11, as it is commonly called,
defines the criteria under which electronic records and electronic signatures are considered to be trustworthy, reliable
and equivalent to paper records (Title 21 CFR Part 11 Section 11.1 (a)).
Practically speaking, Part 11 requires drug makers, medical device manufacturers, biotech companies, biologics
developers, CROs, and other FDA-regulated industries, with some specific exceptions, to implement controls,
including audits, system validations, audit trails, electronic signatures, and documentation for software and systems
involved in processing electronic data that are (a) required to be maintained by the FDA predicate rules or (b) used to
demonstrate compliance to a predicate rule. A predicate rule is any requirement set forth in the Federal Food, Drug
and Cosmetic Act, the Public Health Service Act, or any FDA regulation other than Part 11. [1]
The rule also applies to submissions made to the FDA in electronic format (e.g., a New Drug Application) but not to
paper submissions by electronic methods (i.e., faxes). It specifically does not require the 21CFR11 requirement for
record retention for tracebacks by food manufacturers. Most food manufacturers are not otherwise explicitly required
to keep detailed records, but electronic documentation kept for HACCP and similar requirements must meet these
requirements.
As of 2007, broad sections of the regulation have been challenged as excessive, and the FDA has stated in guidance
that it will exercise enforcement discretion on many parts of the rule. This has led to confusion on exactly what is
required, and the rule is being revised. (An update was posted on April 1, 2010 on the FDA Website). In practice, the
requirements on access controls are the only part routinely enforced. The "predicate rules" which required the
records to be kept in the first place are still in effect. If electronic records are illegible, inaccessible, or corrupted the
manufacturers are still subject to those requirements.
If a regulated firm keeps "hard copies" of all required records, the paper documents can be considered to be the
authoritative document for regulatory purposes and the computer system need not meet these requirements. Firms
should be careful to make a claim that "hard copies" of required records are authoritative document. In order for the
"hard copy" produced from its electronic source be considered as the authoritative document, the "hard copy" must
(a) be a complete and accurate copy of its electronic source and (b) be used exclusively for regulated activities. The
current technical architecture of computer systems increasingly makes the burden of proof for the complete and
accurate copy requirement extremely high.
Content
• Subpart A – General Provisions
• Scope
• Implementation
• Definitions
• Subpart B – Electronic Records
• Controls for closed systems
• Controls for open systems
• Signature manifestations
• Signature/record linking
• Subpart C – Electronic Signatures
• General requirements
• Electronic signatures and controls
• Controls for identification codes/passwords
Title 21 CFR Part 11 2
History
• FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997) [2]
Various keynote speeches by FDA insiders early in the 21st century (in addition to high-profile audit findings
focusing on computer system compliance) resulted in many companies scrambling to mount a defense against rule
enforcement that they were procedurally and technologically unprepared for. Many vendors of software and
instrumentation released Part 11 "compliant" updates, which proved to be either incomplete or insufficient to fully
comply with the rule. Complaints about the wasting of critical resources, non-value added aspects, in addition to
confusion within the drug, medical device, biotech/biologic and other industries about the true scope and
enforcement aspects of Part 11 resulted in the FDA release of:
• FDA Guidance for Industry Part 11, Electronic Records: Electronic Signatures – Scope and Application (2003) [3]
This document was intended to clarify how Part 11 should be implemented and would be enforced. But, as with all
FDA guidances, it was not intended to convey the full force of law—rather, it expressed the FDA's "current
thinking" on Part 11 compliance. Many within the industry, while pleased with the more limited scope defined in the
guidance, complained that, in some areas, the 2003 guidance contradicted requirements in the 1997 Final Rule.
• Guidance for Industry Computerized Systems Used in Clinical Investigations [4]
In May 2007, the FDA issued the final version of their guidance on computerized systems in clinical investigations.
This guidance supersedes the guidance of the same name dated April 1999; and supplements the guidance for
industry on Part 11, Electronic Records; Electronic Signatures — Scope and Application and the Agency’s
international harmonization efforts when applying these guidances to source data generated at clinical study sites.
FDA had previously announced that a new Part 11 would be released late 2006. The Agency has since pushed that
release date back. The FDA has not announced a revised time of release. John Murray, member of the Part 11
Working Group (the team at FDA developing the new Part 11), has publicly stated that the timetable for release is
"flexible."
External links
• 21CFRPart11.com [5]
• Organization: IT Pharma Validation Europe - www.it-validation.eu [6]
• FDA:
• Title 21 Code of Federal Regulations (21 CFR Part 11) [7]
• FDA announcement 08-July-2010(21 CFR Part 11) [8]
• FDA Regulation 21 CFR Part 11 - Electronic Records; Electronic Signatures (1997) [9]
• General Principles of Software Validation; Final Guidance for Industry and FDA Staff (2002) [10]
• FDA Guidance for Industry Part 11, Electronic Records: Electronic Signatures – Scope and Application (2003)
[11]
• EU:
• (European Annex 11) [12]
• (Computerised Systems (revision January 2011)) [13]
Title 21 CFR Part 11 3
References
[1] http:/ / www. fda. gov/ regulatoryinformation/ guidances/ ucm125067. htm
[2] http:/ / www. accessdata. fda. gov/ scripts/ cdrh/ cfdocs/ cfCFR/ CFRSearch. cfm?CFRPart=11& showFR=1
[3] http:/ / www. fda. gov/ downloads/ RegulatoryInformation/ Guidances/ UCM124946. pdf
[4] http:/ / www. fda. gov/ downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ UCM070266. pdf
[5] http:/ / www. 21cfrpart11. com/
[6] http:/ / www. it-validation. eu/
[7] http:/ / www. accessdata. fda. gov/ scripts/ cdrh/ cfdocs/ cfCFR/ CFRSearch. cfm?CFRPart=11
[8] http:/ / www. fda. gov/ AboutFDA/ CentersOffices/ CDER/ ucm204012. htm
[9] http:/ / www. accessdata. fda. gov/ scripts/ cdrh/ cfdocs/ cfcfr/ CFRSearch. cfm?CFRPart=11
[10] http:/ / www. fda. gov/ MedicalDevices/ DeviceRegulationandGuidance/ GuidanceDocuments/ ucm085281. htm
[11] http:/ / www. fda. gov/ downloads/ Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ UCM072322. pdf
[12] http:/ / ec. europa. eu/ health/ files/ eudralex/ vol-4/ pdfs-en/ anx11_en. pdf
[13] http:/ / ec. europa. eu/ health/ files/ eudralex/ vol-4/ annex11_01-2011_en. pdf
Article Sources and Contributors 4
Article Sources and Contributors
Title 21 CFR Part 11 Source: http://en.wikipedia.org/w/index.php?oldid=478665867 Contributors: Alexius08, ArnoldReinhold, Barrymatfield, Brownh2o, David Hawley, Edcolins, Erikg1616,
Fdaregulatory, Figz, GCW50, Ground Zero, Helgeweissig, Hevoila, JP75, Jlculp, Kentmoraga, Labscientist, MarmotteNZ, Mishka.medvezhonok, Pvosta, RightSideNov, Rrburke, Schapel,
Soulattack, Steve Vinson, Vhuynh, Woohookitty, 41 anonymous edits
License
Creative Commons Attribution-Share Alike 3.0 Unported
//creativecommons.org/licenses/by-sa/3.0/
